While the reduction in price target from $16 to $15 by Citigroup could suggest a slightly less optimistic outlook on Editas Medicine's future stock performance, the maintenance of a Buy rating indicates a continued positive view on the company's prospects. This mixed signal might lead to a neutral short-term impact on the stock price, as the market digests both the positive endorsement and the reduced price target.